Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease

• 作者: Steven N.Austad Scott Ballinger Thomas W.Buford Christy S.Carter Daniel L.Smith Jr Victor Darley-Usmar Jianhua Zhang
• 来源期刊: 药学学报（英文版）
• 年，卷（期）: 2022,（2）
• 所属期刊栏目: Special Column: Drug target and drug development for Alzheimer's disease
• 页码范围: 511-531
• 页数: 21页
• 语种: 英文

摘要

Aging is by far the most prominent risk factor for Alzheimer's disease(AD),and both aging and AD are associated with apparent metabolic alterations.As developing effective therapeutic interven-tions to treat AD is clearly in urgent need,the impact of modulating whole-body and intracellular meta-bolism in preclinical models and in human patients,on disease pathogenesis,have been explored.There is also an increasing awareness of differential risk and potential targeting strategies related to biological sex,microbiome,and circadian regulation.As a major part of intracellular metabolism,mitochondrial bioen-ergetics,mitochondrial quality-control mechanisms,and mitochondria-linked inflammatory responses have been considered for AD therapeutic interventions.This review summarizes and highlights these ef-forts.